|
Aug 10
|
Verastem Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 7
|
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 7
|
Verastem: Q2 Earnings Snapshot
|
|
Aug 7
|
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
|
|
Aug 5
|
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates
|
|
Jul 31
|
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
|
|
Jul 29
|
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jul 24
|
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
|
|
Jul 14
|
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial
|
|
Jul 11
|
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
|
|
Jun 30
|
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
|
|
Jun 24
|
Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375
|
|
Jun 24
|
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
|
|
Jun 20
|
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
|
|
May 28
|
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
|
|
May 28
|
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
|
|
May 27
|
US High Growth Tech Stocks to Watch in May 2025
|
|
May 23
|
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC
|
|
May 22
|
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
|
|
May 20
|
Tempus partners with Verastem for companion diagnostic development
|